Alefacept in corticosteroid refractory graft versus host disease: Early results indicate promising activity

Amir A. Toor, Patrick J. Stiff, Brian J. Nickoloff, Tulio Rodriguez, Jared L. Klein, Kenneth B. Gordon*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Steroid refractory graft versus host disease (GVHD) presents a significant therapeutic challenge due to the limited efficacy and safety of second-line treatments. Three patients with extensively pretreated, refractory GVHD were treated with a targeted anti-T-cell agent, alefacept, and demonstrated rapid and clinically significant improvement in their GVHD, facilitating tapering of corticosteroids. The pathological and immunohistochemical findings of GVHD also improved, validating our clinical impression. These preliminary findings indicate that alefacept may have beneficial activity in GVHD warranting further study.

Original languageEnglish (US)
Pages (from-to)13-18
Number of pages6
JournalJournal of Dermatological Treatment
Volume18
Issue number1
DOIs
StatePublished - 2007

Keywords

  • Alefacept
  • CD2
  • Corticosteroid refractory
  • Graft versus host disease
  • T cells

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Alefacept in corticosteroid refractory graft versus host disease: Early results indicate promising activity'. Together they form a unique fingerprint.

Cite this